Primary pigmented nodular adreno-cortical disease

John Connelly Morna MacNeill

Abstract

Cushing's syndrome can cause significant morbidity, effective treatment requires integrated clinical, biochemical, and radiological assessments to reach an accurate diagnosis. Primary pigmented nodular adreno-cortical disease (PPNAD) is an uncommon cause of ACTH-independent Cushing's. Diagnosis can be challenging, in particular where the radiological findings are normal or suggestive of a unilateral process. The condition is very commonly associated with Carney complex and referral for evaluation by a clinical genetics team is essential. The pathological features have been well documented, and there are specific findings which should prompt consideration of a hereditary aetiology.

Keywords adrenal hyperplasia; carney complex; cushing's syndrome

Case report

An adult presented with the symptoms and signs of Cushing's Syndrome and was found to have hypercortisolaemia resistant to dexamethasone suppression. CT imaging of the adrenal glands demonstrated the presence of unilateral nodularity and laparoscopic adrenalectomy was performed. On macroscopic assessment, the adrenal was found to contain several pigmented subcapsular nodules. Histology showed these nodules to be comprised of cells with abundant granular eosinophilic cytoplasm with granular brown pigment (Figure 1). Similar nodules were identified in extra-adrenal fat (Figure 2). The pigment granules stained with PAS but not with Masson-Fontana, Ziehl-Neelsen, Sudan Black, or Perl's Prussian blue. Immunohistochemistry showed that the cells expressed melan A, inhibin, and synaptophysin. A pathological diagnosis of PPNAD was made. The reporting pathologist recommended referral to the clinical genetics service.

Discussion

Cushing's Syndrome, first described by Harvey W. Cushing in 1932, arises from an excess of glucocorticoids, which may be endogenous

John Connelly BMedSci(Hons) MBChB(Hons) MRCP(UK) PGCert ECAT Clinical Lecturer and Honorary Specialty Trainee in Histopathology, Department of Pathology, Royal Infirmary of Edinburgh and University of Edinburgh, UK. Conflicts of interest: none declared.

Morna MacNeill MBChB FRCPath PGCert Consultant Histopathologist, Department of Pathology, Royal Infirmary of Edinburgh, Edinburgh, UK. Conflicts of interest: none declared. This Short Case is brought to you in association with the Pathological Society of Great Britain and Ireland. Each month we feature a Short Case written by a member of the Trainees' Subcommittee of the Pathological Society of Great Britain and Ireland. The Short Case includes a series of Test Yourself Questions at the end to check your understanding of the case. We hope you enjoy reading it.



or exogenous in origin.1 Cushing's syndrome causes a range of symptoms and signs including weight gain, muscle weakness, hair loss, skin fragility, abdominal striae, and easy bruising. It is associated with various complications including diabetes mellitus, hypertension, risk of fracture, impaired wound healing, and psychiatric disturbances. Of the endogenous cases of Cushing's syndrome, around 80% are ACTH-dependent and 20% ACTH-independent. These may be distinguished by dexamethasone suppression testing, with resistance to suppression observed in ACTHindependent cases. The majority of cases of ACTH-independent Cushing's are due to adrenal lesions such as adenomas, or, less commonly, adrenocortical carcinomas. Bilateral adrenal hyperplasia accounts for less than 5% of ACTH-independent cases and are sub-classified as macro- or micro-nodular based on a size threshold of 1 cm.² Primary pigmented nodular adreno-cortical disease (PPNAD) is an uncommon, but important, entity within the category of bilateral adrenal hyperplasia.² Interpretation of preoperative findings in patients with PPNAD can be challenging. In addition to biochemical evaluation, radiology is required usually with MRI of the pituitary gland (expected to be normal) and CT of the adrenals, the findings of which can be variable and confounding - in particular the presence of normal or unilateral adrenal changes does not exclude a diagnosis of PPNAD.³ The differential diagnosis for adrenal enlargement is shown in Table 1.

The term PPNAD was first coined in 1984 by Shenoy et al., based on a retrospective review of 4 cases at the Mayo Clinic in Rochester.⁴ These cases were subsequently revisited in 2014 by Carney et al.⁵ They reported a comprehensive macroscopic, microscopic,




Figure 1 Adrenal gland H&E section, low power view demonstrating a nodule composed of polygonal cells with granular eosinophilic cytoplasm and cytoplasmic lipochrome pigment.




Figure 2 Adrenal gland H&E section, high power view demonstrating extra adrenal extension.

Differential diagnosis for adrenal enlargement

- 1. Neoplasms
 - a) Adenoma
 - b) Adrenocortical carcinoma
 - c) Pheochromocytoma
 - d) Metastasis, most commonly from the lung
 - e) Other neoplasms such as neuroblastoma, ganglioneuroma, myelolipoma, lymphoma, haemangioma, haemangiosarcoma, lymphangiosarcoma, teratoma
- 2. Adrenocortical hyperplasia
- 3. Granulomatous processes
 - a) Tuberculosis
 - b) Histoplasmosis
- 4. Cystic lesions
 - a) Epithelial
 - b) Endothelial
 - c) Pseudocysts
 - d) Parasitic
- 5. Haemorrhage or haematoma
- 6. Abscess

Table 1

and immunohistochemical characterisation of the adrenals in the series. They found that the adrenals together weighed between around 5 and 9 grams.⁵ The glands showed dark pigmentation of the external surface and grossly evident multi-nodularity. Microscopy demonstrated unencapsulated nodules composed of circumscribed aggregates of large, polygonal cells with eosinophilicgranular to clear-vacuolated cytoplasm. Occasional cells showed features such as binucleation, larger more bizarre nuclei, and rare mitotic activity.⁵ Cortical atrophy was observed between the nodules.⁵ Cytoplasmic lipochrome pigment was often present and usually positive for PAS, Ziehl-Neelsen, and Masson Fontana.⁵ Cytoplasmic reactivity was variably seen with immunohistochemistry to inhibin A, synaptophysin, melan A, and Ki-67. Extraadrenal extension has been noted in several instances of hereditary bilateral adrenal hyperplasia and its presence should specifically raise suspicion of a germline disorder.⁵

PPAND is associated with Carney complex in a large majority, >90%, of cases.⁶ This is an autosomal dominant condition comprising myxomas of the heart and skin, mucocutaneous lentiginosis, psammomatous melanotic schwannomas, and endocrine pathologies (namely, PPNAD).⁷ The condition is caused by mutations on *PRKAR1A*, a tumour-suppressor gene found on chromosome 17, which encodes a regulatory subunit of protein kinase A.⁸

Bilateral laparoscopic adrenalectomy is the favoured treatment for PPNAD with demonstrable Cushing's syndrome. Following this, the patient will require life-long hormone replacement with both glucocorticoid and mineralocorticoid. Consideration should also be given to excluding the presence of co-existent cardiac and thyroid diseases. Additionally, a referral to clinical genetics should be considered in all cases. •

REFERENCES

- 1 Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing's syndrome. *Lancet* 2015 Aug 29: 386: 913–27.
- 2 Lacroix A. ACTH-independent macronodular adrenal hyperplasia. Best Pract Res Clin Endocrinol Metabol 2009 Apr 1; 23: 245—59.
- 3 Vezzosi D, Tenenbaum F, Cazabat L, et al. Hormonal, radiological, NP-59 scintigraphy, and pathological correlations in patients with Cushing's syndrome due to primary pigmented nodular adrenocortical disease (PPNAD). J Clin Endocrinol Metab 2015 Nov: 100: 4332–8.
- **4** Shenoy BVMD, Carpenter PCMD, Carney JAMD. Bilateral primary pigmented nodular adrenocortical disease: rare cause of the Cushing syndrome. *J Surg Pathol* 1984 May; **8:** 335–44.
- 5 Carney JA, Libé R, Bertherat J, Young WF. Primary pigmented nodular adrenocortical disease: the original 4 cases revisited after 30 Years for follow-up, new investigations, and molecular genetic findings. Am J Surg Pathol 2014 Sep; 38: 1266–73.
- 6 Manipadam MT, Abraham R, Sen S, Simon A. Primary pigmented nodular adrenocortical disease. J Indian Assoc Pediatr Surg 2011; 16: 160–2.
- 7 Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. *J Clin Endocrinol Metab* 2001 Sep 1; 86: 4041–6.
- 8 Kirschner LS, Carney JA, Pack SD, et al. Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex. Nat Genet 2000 Sep; 26: 89–92.

Practice points

- PPNAD is an uncommon cause of ACTH-independent Cushing's syndrome which is a biochemical diagnosis based on elevated plasma cortisol resistant to the dexamethasone suppression test.
- PPNAD affects both adrenals but counter-intuitively can present with unilateral, or even normal, findings on imaging, making interpretation of pre-operative findings particularly challenging.
- The vast majority of cases of PPNAD are associated with the Carney complex which is most commonly due to mutations in PRKAR1A on chromosome 17.
- Usual treatment involves laparoscopic bilateral adrenalectomy followed by long-term hormone replacement, screening for associated conditions, and referral to clinical genetics.

Self-assessment

- (1) Which of the following biochemical or radiological features is not seen in PPNAD?
 - a. Elevated plasma ATCH
 - b. Elevated plasma cortisol
 - c. Resistance to dexamethasone-suppression
 - d. Unilateral adrenal enlargement
 - e. Pituitary enlargement on MRI
- (2) Which of the following histological features should cause the pathologist to consider a germline aetiology in an adrenal lesion:
 - a. Adjacent cortical atrophy
 - b. Eosinophilic granular cytoplasm

- c. Extra-adrenal extension
- d. Necrosis
- e. Mitotic activity
- (3) What percentage of cases of PPNAD are associated with Carney Complex
 - a. 0-20%
 - b. 20-40%
 - c. 40-60%
 - d. 60-80%
 - e. >80%

Correct answers - 1:e, 2:c, 3:e.